Page 82 - Read Online

Page 812 Tucker et al. Cancer Drug Resist 2019;2:803-12 I http://dx.doi.org/10.20517/cdr.2019.09

46. Krytska K, Ryles HT, Sano R, Raman P, Infarinato NR, et al. Crizotinib Synergizes with chemotherapy in preclinical models of
neuroblastoma. Clin Cancer Res 2016;22:948-60.
47. Carr-Wilkinson J, O’Toole K, Wood KM, Challen CC, Baker AG, et al. High frequency of p53/MDM2/p14ARF pathway abnormalities
in relapsed neuroblastoma. Clin Cancer Res 2010;16: 1108-18.
48. Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound
ALK mutations in ALK-positive lung cancer. Cancer Discov 2018;8:714-29.
49. Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, et al. Resensitization to crizotinib by the lorlatinib ALK resistance
mutation L1198F. N Engl J Med 2016;374:54-61.
50. Debruyne DN, Bhatnagar N, Sharma B, Luther W, Moore NF, et al. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma
is associated with AXL activation and induction of EMT. Oncogene 2016;35:3681-91.
51. Redaelli S, Ceccon M, Zappa M, Sharma GG, Mastini C, et al. Lorlatinib treatment elicits multiple on- and off-target mechanisms of
resistance in ALK-driven cancer. Cancer Res 2018;78:6866-80.
52. Padovan-Merhar OM, Raman P, Ostrovnaya I, Kalletla K, Rubnitz KR, et al. Enrichment of targetable mutations in the relapsed
neuroblastoma genome. PLoS Genet 2016;12:e1006501.
53. Chen L, Humphreys A, Turnbull L, Bellini A, Schleiermacher G, et al. Identification of different ALK mutations in a pair of
neuroblastoma cell lines established at diagnosis and relapse. Oncotarget 2016;7:87301-11.
54. Eleveld, TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway
mutations. Nat Genet 2015;47:864-71.
55. Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, et al. Emergence of new ALK mutations at relapse of neuroblastoma.
J Clin Oncol 2014;32:2727-34.
56. Umapathy G, Guan J, Gustafsson DE, Javanmardi N, Cervantes-Madrid D, et al. MEK inhibitor trametinib does not prevent the
growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas. Sci Signal, 2017;10.
57. Wood AC, Krytska K, Ryles HT, Infarinato NR, Sano R, et al. Dual ALK and CDK4/6 inhibition demonstrates synergy against
neuroblastoma. Clin Cancer Res 2017;23:2856-68.
58. Moore NF, Azarova AM, Bhatnagar N, Ross KN, Drake LE, et al. Molecular rationale for the use of PI3K/AKT/mTOR pathway
inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Oncotarget 2014;5:8737-49.
59. Schonherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, et al. Anaplastic lymphoma kinase (ALK) regulates initiation of transcription
of MYCN in neuroblastoma cells. Oncogene 2012;31:5193-200.
60. Claeys S, Denecker G, Durinck K, Decaesteker B, Mus LM, et al. ALK positively regulates MYCN activity through repression of
HBP1 expression. Oncogene 2019;38:2690-705.
61. Escamilla-Powers JR, Daniel CJ, Farrell A, Taylor K, Zhang X, et al. The tumor suppressor protein HBP1 is a novel c-myc-binding
protein that negatively regulates c-myc transcriptional activity. J Biol Chem 2010;285:4847-58.
62. Watts E, Heidenreich D, Tucker E, Raab M, Strebhardt K, et al. Designing dual inhibitors of anaplastic lymphoma kinase (ALK) and
bromodomain-4 (BRD4) by tuning kinase selectivity. J Med Chem 2019;62:2618-37.
63. Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther 2018;3:5.